Takeaway
Amyloid-β42 and neurofilament light chain (NfL) are promising plasma biomarkers for the diagnosis of early-stage Alzheimer’s disease (AD).
Why this matters ?
Evaluating AD-related protein biomarkers in plasma could offer a faster and less invasive diagnostic approach for AD than measuring biomarkers in cerebrospinal fluid.